Archive: July 30, 2026

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

Business Wire India

• Solid first quarter performance broadly in line with guidance, underpinned by resilient demand across core in-line brands
• Commercial execution and late-stage pipeline investments on schedule, including first approval for ORZEYFUL^TM (oveporexton) in China, setting the foundation for next wave of medicines
• No change to FY2026 full-year forecast and management guidance

Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined execution and operational momentum. Takeda leveraged the resilient performance of its core in-line portfolio to support its long-term strategy, advancing commercial launch preparations and driving critical R&D pipeline milestones. With a clear operational trajectory established in the first quarter and under a new operating model, Takeda remains on track to deliver its strategic and financial commitments for the fiscal year.

FY2026 First Quarter Highlights

• Revenue increased by +10.2% versus the prior-year period on an actual exchange rate (AER) basis and decreased by -0.5% on a Constant Exchange Rate (CER) basis as the negative impact of the loss of exclusivity of VYVANSE® was largely offset by growth from core in-line brands.
• Core Operating Profit increased by +11.5% on an AER basis and decreased by -0.5% on a CER basis, reflecting continued growth investments supported by the transformation program.
• Reported Operating Profit increased by +9.1% on an AER basis.
• Core EPS increased by +1.5% at AER and decreased by -11.8% at CER, while Reported EPS decreased by -9.8% YoY.
• Adjusted Free Cash Flow amounted to JPY 68.6 billion.
• Launch preparations for key late-stage pipeline assets (ORZEYFUL, rusfertide and zasocitinib) are progressing on schedule, with the first approval for ORZEYFUL achieved in China.
• FY2026 full-year outlook remains unchanged.
• A Capital Markets Day will be held on December 11, 2026, in Tokyo, Japan.

Takeda President and Chief Executive Officer, Julie Kim, commented:
“Our solid performance this quarter marks a good start to the fiscal year and keeps us on track to achieve our full-year targets.

“This quarter’s results reflect our unwavering commitment to financial discipline and the progressing execution of our enterprise transformation. The efficiencies unlocked by this ongoing program are directly fueling our highest priorities in Horizon One in our two-horizon growth strategy: the successful launch of three medicines that have the potential to be blockbuster brands, the advancement of our late-stage pipeline, the enduring resilience of our core in-line portfolio and new capabilities and efficiencies gained through transformation. We look forward to sharing the detailed strategic roadmap for these two growth horizons at our Capital Markets Day in December.”

Takeda Chief Financial Officer, Milano Furuta, commented:
“Our first-quarter performance is tracking consistently with management guidance, with the resilience of our core in-line brands largely offsetting our mature portfolio decline, and OPEX savings through the transformation program being strategically reinvested to fund future growth opportunities. Our full-year forecast and guidance remain unchanged.”

FINANCIAL HIGHLIGHTS for First Quarter Results ended June 30, 2026

Pipeline Progress Building the Foundation for Future Growth
Takeda’s next-generation growth engine is anchored by three, high-potential, late-stage pipeline assets expected to obtain regulatory approvals in the U.S. and other key regions in the coming year. While this represents a pivotal period of strategic investment and commercial launch execution, Takeda is positioned to deliver tangible milestones over the next 12 to 24 months. By establishing a track record of launch excellence today, Takeda is securing the foundation that will underpin the Company’s sustained, long-term growth and meaningful impact for patients globally.

ORZEYFUL

• An orexin receptor agonist with a first-in-class mechanism of action, designed to address the orexin deficiency that causes narcolepsy type 1 (NT1).
• The first approval of oveporexton was recently granted in China under the brand name ORZEYFUL.
• New drug applications are currently under review in the United States and Japan.
• Preparations for the expected launches in the U.S., Japan and China in the second half of the year are well underway.
• At SLEEP 2026, Takeda presented Phase 3 clinical trial results for ORZEYFUL demonstrating improvements in daily functioning, cognition and nighttime sleep in patients with narcolepsy type 1.

Rusfertide

• A potential first-in-class hepcidin mimetic for the treatment of adults with the blood cancer polycythemia vera (PV).
• Demonstrated significant improvements in hematocrit control and phlebotomy reduction for patients with PV in a Phase 3 clinical trial.
• Granted Priority Review by the U.S. FDA, Takeda is prepared for a commercial U.S. launch expected in the second half of 2026.

Zasocitinib

• A next generation, highly selective and potent TYK2 inhibitor that has demonstrated rapid, durable skin clearance in a convenient once-daily oral pill with no fasting restrictions.
• Achieved positive topline results across the primary endpoint and all key secondary endpoints in a head-to-head Phase 3 clinical trial against deucravacitinib.
• Achieved consistent, high rates of skin clearance across the body, including hard-to-treat and high-impact sites in Phase 3 psoriasis studies.
• Takeda is making the necessary investments with a view toward regulatory submissions in 2026 and a commercial launch anticipated in the first half of 2027.

Capital Allocation and Shareholder Returns
Takeda maintains a disciplined capital allocation framework that prioritizes investments in new launches and R&D innovation with the goal of driving growth and enabling the company to deliver returns to shareholders under its progressive dividend policy. The annual dividend forecast for FY2026 is JPY 204 per share.

Additional Information Regarding FY2026 First Quarter Results
Takeda will host a conference call for investors and analysts on Thursday, July 30, 2026, at 19:00 Japan Time / 6:00 U.S. Eastern Time to discuss its FY2026 first quarter results.

A live webcast of the conference call and the presentation materials will be available in the Investor Relations section of Takeda’s website (www.takeda.com/investors). The presentation materials include details on Takeda’s FY2026 first quarter results, business progress and pipeline updates, as well as definitions of non-IFRS measures.

About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit https://www.takeda.com.

Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including drug pricing, tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Financial information and Non-IFRS Measures

Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).

This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate (“CER”) change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures, which are in the Financial Appendix appearing at the end of our FY2026 Q1 investor presentation (available at www.takeda.com/investors).

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260727883646/en/

Kioxia Introduces First PCIe® 6.0 Enterprise SSDs Utilizing Newest BiCS FLASH™ Generation 10 Flash Memory

Business Wire India

Kioxia Corporation today announced the KIOXIA CM10 Series of solid-state drives (SSDs), featuring the company’s latest BiCS FLASH™ generation 10 TLC flash memory. Designed for demanding enterprise and AI workloads, including AI inference and context caching, the new drives support the NVIDIA CMX™ architecture while delivering significant gains in performance, power efficiency, and cooling flexibility over the previous generation⁽¹⁾.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729732832/en/

KIOXIA CM10 Series Enterprise SSD

The KIOXIA CM10 Series is Kioxia’s first PCIe^® 6.0 enterprise SSD and offers direct-cold-plate liquid cooling capability, enabling more efficient cooling deployments for next-generation AI infrastructure. Compared to the previous generation⁽¹⁾, the KIOXIA CM10 Series delivers up to approx. 92 % higher sequential read performance and up to approx. 85 % higher random read performance, helping to accelerate data-intensive AI inference and enterprise applications while improving overall system efficiency.

As AI models continue to scale toward trillions of parameters and context windows expand to millions of tokens, the demand for high-performance context cache storage is growing rapidly. Architectures such as NVIDIA CMX™ extend the memory hierarchy beyond GPU memory by leveraging ultra-fast flash memory storage, making enterprise SSDs an increasingly important component of AI infrastructure. The KIOXIA CM10 Series is designed to meet these evolving requirements with the performance, capacity, and endurance needed for large-scale AI deployments.

Key features of the KIOXIA CM10 Series include:

• PCIe 6.0, NVMe™ 2.1, and Open Compute Project(OCP) Datacenter NVMe SSD Specification v2.7⁽²⁾ compliant, including support for NVMe Flexible Data Placement (FDP)
• Available in E3.S, E1.S, and 2.5-inch⁽³⁾ form factors, with cold-plate liquid cooling capability in E3.S and E1.S 9.5mm form factors (all form factors support traditional air-cooled environments)
• Capacities ranging from 1.60 TB to 61.44 TB (varies by form factor), with read-intensive (1 DWPD) and mixed-use (3 DWPD) endurance options
• Utilizes leading-edge KIOXIA BiCS FLASH™ generation 10 (332-layers) flash memory that improves SSD performance and power efficiency
• Security options include SIE, SED, SED FIPS 140-3 (planned), post-quantum cryptography recommended by CNSA 2.0, and SPDM 1.4 attestation support

The KIOXIA CM10 Series drives are currently sampling to select customers⁽⁴⁾, and will be showcased at FMS: the Future of Memory and Storage, taking place August 4 – 6 in Santa Clara, Calif.

Notes:
(1): Compared to KIOXIA CM9 Series SSDs
(2): Not all requirements of the OCP Datacenter NVMe SSD specification v2.7 are supported
(3): The 2.5-inch form factor product is PCIe 5.0 compliant and uses BiCS FLASH™ generation 8 TLC flash memory
(4): These samples are for the functional check purpose only and the specifications of the samples may differ in mass production

2.5-inch indicates the form factor name and not its physical size.

Read and write speed may vary depending on various factors such as host devices, software (drivers, OS etc.), and read/write conditions.

Definition of capacity: Kioxia Corporation defines a megabyte (MB) as 1,000,000 bytes, a gigabyte (GB) as 1,000,000,000 bytes and a terabyte (TB) as 1,000,000,000,000 bytes. A computer operating system, however, reports storage capacity using powers of 2 for the definition of 1GB = 2^30 bytes = 1,073,741,824 bytes and 1TB = 2^40 bytes = 1,099,511,627,776 bytes and therefore shows less storage capacity. Available storage capacity (including examples of various media files) will vary based on file size, formatting, settings, software and operating system, and/or pre-installed software applications, or media content. Actual formatted capacity may vary.

DWPD: Drive Writes Per Day. One full drive write per day means the drive can be written and re-written to full capacity once a day every day under the specified workload for the specified lifetime. Actual results may vary due to system configuration, usage and other factors.

SED optional model supports TCG Opal SSC except for some features.
SED optional model is not available in all countries due to the local regulations.

NVIDIA is a trademark and/or registered trademark of NVIDIA Corporation in the U.S. and other countries.

NVMe is a registered or unregistered mark of NVM Express, Inc. in the United States and other countries.

OCP and OPEN COMPUTE PROJECT marks are owned by and used with the permission of the Open Compute Project Foundation.

PCIe is a registered trademark of PCI-SIG.

Other company names, product names and service names may be trademarks of third-party companies.

About Kioxia

Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. Kioxia is committed to uplifting the world with “memory” by offering products, services and systems that create choice for customers and memory-based value for society. Kioxia’s innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, automotive systems, data centers and generative AI systems.

*Information in this document, including product prices and specifications, content of services and contact information, is correct on the date of the announcement but is subject to change without prior notice.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260729732832/en/

Grid Dynamics Accelerates Enterprise AI-Native Transformation With Workforce Certification and GAIN Platforms Rollout

Business Wire India

Key Takeaways:

• Grid Dynamics plans to have 90% of its engineers trained and certified on Anthropic and OpenAI platforms by the end of October 2026.
• At one of North America’s largest home improvement retailers, Grid Dynamics has scaled its GAIN (Grid Dynamics AI Native) Platform for AI SDLC by expanding its agentic harness technology to more than 500 additional engineers.

Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a leading provider of technology consulting, platform and product engineering, and AI-driven digital transformation services, today announced significant momentum in the adoption of its enterprise agentic AI solutions. Organizations across retail, financial services, manufacturing, CPG, and logistics industries are increasingly deploying Grid Dynamics’ agentic AI-native platforms and Forward Deployed Engineering (FDE)-led services to accelerate software delivery, improve operational efficiency, and transform business processes at scale. Grid Dynamics is widely recognized for its enterprise AI expertise and delivery capabilities across Fortune 1000 organizations.

Grid Dynamics has partnership agreements with Anthropic and OpenAI to accelerate the adoption of these platforms within enterprises. By the end of October 2026, Grid Dynamics plans to have 90% of its engineers trained and certified on these platforms. Built to support complex enterprise environments, Grid Dynamics’ GAIN platforms use advanced agentic meta-harness technologies, including integrations with Anthropic Claude and OpenAI Codex to orchestrate multi-step workflows, automate knowledge-intensive processes, and enable intelligent collaboration between human experts and AI systems.

Over the past year, enterprise demand for agentic AI has accelerated substantially as organizations move beyond experimentation toward production-scale deployments. Grid Dynamics has seen growing adoption of its solutions among some of the world’s largest retailers, financial institutions, manufacturers, CPG companies, and logistics providers seeking measurable business outcomes from AI investments.

Reflecting this growing demand, Grid Dynamics recently expanded deployment of its agentic harness technology to support more than 500 additional engineers at one of North America’s largest home improvement retailers. The expansion represents one of several large-scale enterprise rollouts completed by the company as customers increasingly standardize on AI-powered software development and delivery frameworks.

“Enterprise AI is entering a new phase where organizations are no longer evaluating isolated use cases. They are building AI-native operating models,” said Rahul Bindlish, Senior Vice President of Global Partnerships and Marketing at Grid Dynamics. “Our GAIN platforms help clients operationalize agentic AI at scale, enabling teams to automate complex workflows, accelerate decision-making, and unlock new levels of productivity across the enterprise.”

The company continues to invest in AI-native engineering methodologies, enterprise-grade governance, and scalable delivery frameworks that help organizations transition from pilot programs to enterprise-wide adoption.

“Organizations are looking for trusted partners that can combine deep AI expertise with proven enterprise delivery capabilities,” added Bindlish. “We believe agentic AI will become a foundational technology layer across every major industry, and we are committed to helping our clients realize AI’s full potential.”

About Grid Dynamics

Grid Dynamics (Nasdaq: GDYN) is a premier AI transformation partner for the Fortune 1000. We combine deep AI expertise with proven enterprise-scale delivery to help clients identify where to invest in AI, build systems that work at scale, and capture real business value from AI deployments. A key differentiator for Grid Dynamics is our nearly two decades of technology leadership and pioneering enterprise AI expertise. Founded in 2006, Grid Dynamics is headquartered in Silicon Valley with offices across the Americas, Europe, and India.

To learn more about Grid Dynamics, please visit https://www.griddynamics.com. Follow us on LinkedIn.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that are not historical facts, and involve risks and uncertainties that could cause actual results of Grid Dynamics to differ materially from those expected and projected. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “may,” “will,” “potential,” “projects,” “predicts,” “continue,” or “should,” or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include, without limitation, quotations and statements regarding the expected benefits of our capabilities and our company’s future growth including with customers and partners. Most of these factors are outside Grid Dynamics’ control and are difficult to predict. Factors that may cause such differences include, but are not limited to, our ability to achieve expected benefits, any factors limiting our capabilities, the benefits of our services and products, and our company’s growth strategy.

Grid Dynamics cautions that the foregoing list of factors is not exclusive. Grid Dynamics cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Grid Dynamics does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Further information about factors that could materially affect Grid Dynamics, including its results of operations and financial condition, is set forth under the “Risk Factors” section of Grid Dynamics’ annual report on Form 10-K filed March 5, 2026, and in other periodic filings Grid Dynamics makes with the SEC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260729981480/en/